In response to inquiries, CooperVision today confirmed that the recent ruling on February 12, 2009 by the Netherlands’ court upholding Ciba Vision’s silicone hydrogel patent and enjoining Johnson & Johnson’s Acuvue®Oasys™ contact lens from the Netherlands’ market does not impact the supply or servicing of CooperVision’s customers with Biofinity® and Avaira® on a worldwide basis. CooperVision has previously entered into a license agreement with Ciba Vision whereby CooperVision has unrestricted worldwide rights under the patent asserted against J&J.

Biofinity and Avaira offer unique Aquaform™ technology creating a naturally wettable, exceptionally comfortable lens for the contact lens patient.  Biofinity has received approval by the FDA for extended wear.

“Biofinity and Avaira contact lenses are third generation silicone hydrogel lenses that offer premium performance and a high level of wearing comfort,” stated John Weber, president of CooperVision.